<DOC>
	<DOC>NCT02929095</DOC>
	<brief_summary>Percutaneous trans-arterial angioplasty(PTA) is one of the peripheral arterial occlusive disease(PAOD) treatment. During and after PTA, ischemia-reperfusion pain is induced so proper analgesia is important. ischemia-reperfusion injury is due to reactive oxygen species. Dexmedetomidine has analgesic, sedative and anti oxidant effect. So the investigators research the patient's satisfaction that are given the dexmedetomidine during PTA procedure.</brief_summary>
	<brief_title>The Effect of Remifentanil-dexmedetomidine Compared With Remifentanil-midazolam on Patient's Satisfaction</brief_title>
	<detailed_description />
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Dexmedetomidine</mesh_term>
	<mesh_term>Remifentanil</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>patients who are scheduled to undergo percutaneous transarterial angioplasty American Society of Anesthesiologists (ASA) class I, II, III Subjects are ineligible if they have the below condition psychiatric medication myocardial infarction within 1 year cardiac surgery within 1 year heart failure fever (&gt;38 degree) uncontrolled hypertension cognitive dysfunction disabling mental change disorder being unable to communicate or speak Korean</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>